CYTK · Categories · Downgrades
CYTK - Analyst downgrades
Cytokinetics Incorporated (CYTK) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for CYTK
- Cytokinetics downgraded by Goldman with a new price targetGoldman downgraded Cytokinetics from Buy to Neutral and set a new price target of $60.00 from $85.00 previously
- Cytokinetics downgraded by UBS with a new price targetUBS downgraded Cytokinetics from Buy to Neutral and set a new price target of $92.00 from $61.00 previously
- Cytokinetics downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Cytokinetics from Overweight to Equal-Weight and set a new price target of $90.00 from $60.00 previously